Pipeline products are under clinical investigation and have not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication.
Legend:
Externally Derived Molecule
Internally Derived Molecule
Chemical Entity
Biological Entity 1
First Line treatment
1M
First Line maintenance treatment
2
Second Line treatment
3
Third Line treatment
4
As announced on March 23 2017, the US FDA has granted accelerated approved of avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). This indication was approved under accelerated approval based on tumor response and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Avelumab has not yet been approved for metastatic MCC outside of the US.
5
On April 24 2017, the divestment of Merck’s Biosimilars business to Fresenius was announced. Closing is expected in H2 2017, subject to regulatory approvals and other conditions.
6
Sponsored by the National Cancer Institute (USA).
7
As announced on March 30 2017, in an agreement with Avillion, anti-IL-17 A/F nanobody will be developed by Avillion for plaque psoriasis and commercialized by Merck.